Clinical Trials
Petosemtamab + Pembrolizumab vs. Pembrolizumab in 1st line treatment of PD-L1+ Head & Neck squamous cell carcinoma
Disease Type: Head and Neck
A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville